Bausch Health Companies Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bausch Health Companies Inc. on January 2, 2026. The report details a material definitive agreement entered into by Bausch + Lomb Corporation, a subsidiary of the registrant, regarding the refinancing of its credit facilities.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring rather than operational financial performance metrics such as revenue or profit, which are not provided in this document.
- New Debt Instrument: A new tranche of term loans totaling $2,802,125,000 (Replacement Term Loans).
- Maturity Date: January 15, 2031.
- Amortization: 1.00% per annum, with the first installment due June 30, 2026.
- Interest Margins: 3.75% per annum for term SOFR-based rates; 2.75% per annum for alternate base rate-based loans.
- Refinanced Obligations: Proceeds were used to refinance all outstanding Term B loans due 2031 and Term B loans due 2028.
Material Changes Versus Prior Period
The Fourth Amendment to the Credit Agreement resulted in the following material changes compared to the previous loan structures:
- Interest Rate Reduction: The applicable margin was reduced by 0.50% per annum compared to the Third Amendment Term Loans and by 0.25% per annum compared to the First Incremental Term Loans.
- Maturity Extension: The maturity date for the First Incremental Term Loans was effectively extended from September 29, 2028, to January 15, 2031.
- Consolidation: Multiple existing tranches were consolidated into a single new tranche.
Outlook, Risks, and Management Commentary
Management executed this refinancing to optimize the cost of capital and extend the maturity profile of its debt. The filing does not contain specific forward-looking guidance on revenue or earnings, nor does it detail new risks beyond the standard obligations of the amended credit agreement. The full terms of the agreement are incorporated by reference in Exhibit 10.1.
Key Facts for Investor Verification
- Verify the total principal amount of $2,802,125,000 and the specific allocation of proceeds to retire the 2028 and 2031 Term B loans.
- Confirm the impact of the margin reduction (0.50% and 0.25%) on the company's projected interest expense.
- Review the full text of the Fourth Amendment (Exhibit 10.1) for any new covenants or financial maintenance requirements.
- Note the first amortization payment date of June 30, 2026, for cash flow planning.